Lance Leopold

Trials

Studies that name Lance Leopold as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:10 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT04640025 · A Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Itacitinib

  Incyte Corporation · terminated · Myelofibrosis, Postlung Transplant (Bronchiolitis Obliterans), Chronic Graft Versus Host Disease · study director
• Ph2
  NCT03322540 · Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)

  Incyte Corporation · completed · Lung Cancer · study director
• Ph2
  NCT03322566 · A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06)

  Incyte Corporation · completed · Lung Cancer · study director
• Ph1/Ph2
  NCT03314935 · A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors

  Incyte Corporation · completed · Biliary Tract Cancer (BTC), Colorectal Cancer (CRC), Endometrial Cancer · study director
• Ph1
  NCT02559492 · Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors

  Incyte Corporation · terminated · Solid Tumors · study director
• Ph1/Ph2
  NCT02327078 · A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)

  Incyte Corporation · completed · B-cell Malignancies, Colorectal Cancer (CRC), Head and Neck Cancer · study director
• Ph1/Ph2
  NCT02318277 · A Study of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)

  Incyte Corporation · completed · Solid Tumors, Head and Neck Cancer, Lung Cancer · study director
• Ph2
  NCT01685255 · A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy

  Incyte Corporation · terminated · Ovarian Cancer, Genitourinary (GU) Tumors · study director
• Ph1/Ph2
  NCT01604889 · A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma

  Incyte Corporation · terminated · Melanoma · study director
• Ph1
  NCT01195311 · A Dose-escalation Study in Subjects With Advanced Malignancies

  Incyte Corporation · completed · Solid Tumors and Hematologic Malignancy · study director
• Ph1
  NCT01072266 · A Dose-escalation Study in Subjects With Advanced Malignancies

  Incyte Corporation · completed · Solid Tumor, Advanced Cancer, Metastatic Cancer · study director
• Ph2
  NCT00571675 · A Study Comparing AT-101 in Combination With Docetaxel and Prednisone Versus Docetaxel and Prednisone in Men With Chemotherapy-Naïve Metastatic Hormone Refractory Prostate Cancer (HRPC)

  Ascenta Therapeutics · completed · Hormone Refractory Prostate Cancer · study director
• Ph1/Ph2
  NCT00561197 · An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer

  Ascenta Therapeutics · terminated · Locally Advanced Esophageal or GE Junction Cancer · study director
• Ph2
  NCT00544960 · A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer

  Ascenta Therapeutics · completed · Non-small Cell Lung Cancer · study chair
• Ph2
  NCT00440388 · Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma

  Ascenta Therapeutics · completed · Follicular Lymphoma · study director
• Ph1/Ph2
  NCT00397293 · Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer

  Ascenta Therapeutics · completed · Small Cell Lung Cancer · study chair
• Ph1/Ph2
  NCT00286806 · A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer

  Ascenta Therapeutics · completed · Hormone Refractory Prostate Cancer · study director
• Ph1/Ph2
  NCT00286793 · Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC

  Ascenta Therapeutics · completed · Prostate Cancer · study director
• Ph2
  NCT00275431 · Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies

  Ascenta Therapeutics · completed · Follicular Lymphoma, Diffuse Large Cell Lymphoma, Mantle Cell Lymphoma · study director

Grants

NIH projects from RePORTER, fetched 2026-11-12 11:10 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.